Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lurasidone Hydrochloride

FDA-approved product (tablet, oral), marketed as Latuda, Lurasidone Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lurasidone Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bipolar disorder
  • Bipolar I disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Indole derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lurasidone Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lurasidone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Lurasidone and Cognition in Bipolar I Disorder

    NCT02147379 · start 2014-05

    Registered record
    Registry ID
    NCT02147379
    Conditions
    Bipolar I Disorder
    Interventions
    Lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-05
    Completion
    2017-01-12
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder
    InterventionLurasidone
    PhasePhase 3
    Registry statusCompleted

  • Lurasidone Pediatric Bipolar Study

    NCT02046369 · start 2014-03

    Registered record
    Registry ID
    NCT02046369
    Conditions
    Bipolar I Depression
    Interventions
    Lurasidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-03
    Completion
    2016-10
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Depression
    InterventionLurasidone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects

    NCT02174510 · start 2014-03

    Registered record
    Registry ID
    NCT02174510
    Conditions
    Schizophrenia
    Interventions
    20mg lurasidone; 40mg lurasidone; 80mg lurasidone; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-03
    Completion
    2014-04
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Intervention20mg lurasidone; 40mg lurasidone; 80mg lurasidone; placebo
    PhasePhase 1
    Registry statusCompleted

  • A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

    NCT01986101 · start 2014-02-19

    Registered record
    Registry ID
    NCT01986101
    Conditions
    Bipolar Depression
    Interventions
    Placebo; SM-13496; SM-13496
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-02-19
    Completion
    2017-02-16
    Enrolment
    525

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Depression
    InterventionPlacebo; SM-13496; SM-13496
    PhasePhase 3
    Registry statusCompleted

  • A Clinical Trial of Lurasidone in Treatment of Schizophrenia

    NCT02002832 · start 2013-12

    Registered record
    Registry ID
    NCT02002832
    Conditions
    Schizophrenia
    Interventions
    Lurasidone tablets; Risperidone tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12
    Completion
    2015-11
    Enrolment
    388

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone tablets; Risperidone tablets
    PhasePhase 3
    Registry statusCompleted

  • Lurasidone Low-Dose - High-Dose Study Study

    NCT01821378 · start 2013-05

    Registered record
    Registry ID
    NCT01821378
    Conditions
    Schizophrenia
    Interventions
    Lurasidone; Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-05
    Completion
    2014-06
    Enrolment
    412

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone; Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2; Placebo
    PhasePhase 3
    Registry statusCompleted

  • An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

    NCT01498770 · start 2013-04-01

    Registered record
    Registry ID
    NCT01498770
    Conditions
    Bipolar Disorder
    Interventions
    Asenapine; Aripiprazole; Quetiapine; Risperidone; Olanzapine; Ziprasidone; Iloperidone; Paliperidone; Lurasidone; Clozapine; Amisulpride; Sertindole; Zotepine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-04-01
    Completion
    2017-12-21
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionAsenapine; Aripiprazole; Quetiapine; Risperidone +9 more
    PhaseNot recorded
    Registry statusCompleted

  • Lurasidone Effects on Tissue Glutamate in Schizophrenia

    NCT02199743 · start 2013-02

    Registered record
    Registry ID
    NCT02199743
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Lurasidone; Haloperidol; Perphenazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-02
    Completion
    2016-06
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionLurasidone; Haloperidol; Perphenazine
    PhasePhase 4
    Registry statusCompleted

  • Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

    NCT01731119 · start 2012-12

    Registered record
    Registry ID
    NCT01731119
    Conditions
    Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Psychosis NOS; Autistic Disorder; Asperger Syndrome; Child Development Disorders, Pervasive; Bipolar I Disorder; Bipolar II Disorder; Mood Disorder NOS; Severe Major Depression With Psychotic Features; Single Episode Major Depression Without Psychotic Symptoms; Severe Mood Disorder With Psychotic Features
    Interventions
    Latuda©
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-12
    Completion
    2014-08
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Psychosis NOS +9 more
    InterventionLatuda©
    PhasePhase 2
    Registry statusCompleted

  • Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

    NCT01614912 · start 2012-08

    Registered record
    Registry ID
    NCT01614912
    Conditions
    Schizophrenia
    Interventions
    SM-13496
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-08
    Completion
    2015-05
    Enrolment
    284

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionSM-13496
    PhasePhase 3
    Registry statusCompleted

  • A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

    NCT01614899 · start 2012-07-02

    Registered record
    Registry ID
    NCT01614899
    Conditions
    Schizophrenia
    Interventions
    SM-13496 40mg; SM-13496 80mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-07-02
    Completion
    2014-11-17
    Enrolment
    457

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionSM-13496 40mg; SM-13496 80mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296

    NCT01575561 · start 2012-06

    Registered record
    Registry ID
    NCT01575561
    Conditions
    Bipolar I Disorder
    Interventions
    Lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-06
    Completion
    2015-07
    Enrolment
    377

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder
    InterventionLurasidone
    PhasePhase 3
    Registry statusCompleted

  • Major Depressive Disorder With Mixed Features

    NCT01423240 · start 2012-01

    Registered record
    Registry ID
    NCT01423240
    Conditions
    Major Depressive Disorder
    Interventions
    Lurasidone 20 mg; Lurasidone 60 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2012-01
    Completion
    2012-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionLurasidone 20 mg; Lurasidone 60 mg; Placebo
    PhasePhase 3
    Registry statusWithdrawn

  • High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia

    NCT01569659 · start 2011-10

    Registered record
    Registry ID
    NCT01569659
    Conditions
    Schizophrenia
    Interventions
    Lurasidone; Lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-10
    Completion
    2015-07
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone; Lurasidone
    PhasePhase 4
    Registry statusCompleted

  • Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose

    NCT01421134 · start 2011-09

    Registered record
    Registry ID
    NCT01421134
    Conditions
    Major Depressive Disorder With Mixed Features
    Interventions
    Lurasidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09
    Completion
    2014-10
    Enrolment
    211

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder With Mixed Features
    InterventionLurasidone; Placebo
    PhasePhase 3
    Registry statusCompleted